Shanghai Pharmaceuticals Holding (601607.SH): The oral solution of bromhexine hydrochloride has obtained production approval.

Shanghai Pharmaceuticals Holding (601607.SH) announced that recently, its subsidiary Shanghai Shangyi Pharmaceutical Co., Ltd. (referred to as "Shangyi") has received the "Drug Registration Certificate" (Certificate No.: 2025S04074) issued by the National Medical Products Administration for its pyridostigmine oral solution. The drug has been approved for production. Pyridostigmine oral solution is used to treat myasthenia gravis, and was originally developed by BAUSCH and first launched in the United States in 1965. In April 2024, Shangyi submitted an application for registration and market approval of the drug to the National Medical Products Administration, which was accepted. As of the date of the announcement, the company has invested approximately RMB 2.3174 million in research and development for this drug. As of the date of this announcement, there are no other companies in China that have launched this drug.